CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 103 enrolled
Drug / intervention
Chloroquine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02564471
NCT02564471Phase 4Completed
CompareCT.gov

Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-exposure Prophylaxis. A Randomized, Open Label, Trial in Healthy US Adults Age 18-60 Years

State University of New York - Upstate Medical University·interventional·Posted Sep 30, 2015·Updated May 13, 2021

In Brief

A Phase 4 clinical trial evaluating Chloroquine, Atovaquone and Proguanil, and 2 other interventions for Rabies. Completed, enrolled 103 participants across 1 site.

Detailed Summary

This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRabies
CountriesUnited States
CollaboratorsWalter Reed Army Institute of Research (WRAIR), Kansas State University

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 30, 2015
Enrollment StartNov 11, 2016
Primary CompletionAug 1, 2018
Study CompletionFeb 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.8 years ago

Interventions

Chloroquinedrug

FDA approve dosing schedule

Atovaquone and Proguanildrug

FDA approve dosing schedule

Doxycyclinedrug

FDA approve dosing schedule

Rabies Vaccinebiological

FDA approve dosing schedule